CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDY

Brigitta G. Baumert(Kantonsspital Graubünden), Roger Stupp(Northwestern University), Anja Gijtenbeek(Radboud University Nijmegen), Warren Mason(Princess Margaret Cancer Centre), Martin J. van den Bent(Erasmus MC Cancer Institute), Khê Hoang‐Xuan(Sorbonne Université), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Jeremy Rees(National Hospital for Neurology and Neurosurgery), Michael Weller(University Hospital of Zurich), Wolfgang Wick(Heidelberg University), Jacoline E. C. Bromberg(Erasmus MC), Paul Sargos, Anna S. Berghoff(Medical University of Vienna), Élodie Vauléon(Université Claude Bernard Lyon 1), Brian Thiessen(Princess Margaret Hospital), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Roelien H. Enting(University of Groningen), Claire Phillips(Peter MacCallum Cancer Centre), Tzahala Tzuk(Rambam Health Care Campus), Monika E. Hegi(University Hospital of Lausanne), Andreas von Deimling(German Cancer Research Center), Martin Taphoorn(Leiden University Medical Center), Carmen Balañá(Institut Català d'Oncologia), Robert Nordal, Pierre Bady(University of Lausanne), Johan M. Kros(Erasmus MC), Olivier Chinot(Aix-Marseille Université), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), F. Dhermain(Institut Gustave Roussy), Denis Lacombe(Medisch Centrum Haaglanden), John P. Rossiter(Queen's University), M.A. Lentz, Paul M. Clément(Universitair Ziekenhuis Leuven), Julian Jacob(Sorbonne Université), Michele Reni(San Raffaele University of Rome)
Neuro-Oncology
November 1, 2024
Cited by 4


Related Papers